Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Phase 2 Completed 49 enrolled Peregrine Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small cell lung cancer.

Timeline

Start: 2008-06
Primary completion: 2010-07
Completion: 2010-07

Publications

Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan JS, Gerber DE. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. Lung Cancer. 2014 Nov;86(2):231-6. doi: 10.1016/j.lungcan.2014.08.010. Epub 2014 Aug 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bavituximab	Monoclonal antibody	3 mg/kg	—
Background	Carboplatin	Small molecule	5 unknown	—
Background	Paclitaxel	Small molecule	175 mg/m2	—

Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Summary

Timeline

Publications

Drugs

Indications